| Amantadine as Adjunctive Therapy to Antipsychotics in Schizophrenia (NCT00999505) | Hospital de Clinicas de Porto Alegre | 2010-05-01 |
| Effects of Galantamine on Cognition (NCT01100775) | University of Maryland, Baltimore | 2010-05-01 |
| Patient Guided Psychiatric Admissions (NCT01133587) | St. Olavs Hospital | 2010-05-01 |
| The Effect of Nicotine on Arousal, Cognition and Social Cognition in Schizophrenic Patients (NCT01186471) | Janssen Pharmaceutica N.V., Belgium | 2010-05-01 |
| Event Marker Ingested To Trigger Event Recorder 3.0 Psychiatry Study (NCT01804257) | Proteus Digital Health, Inc. | 2010-05-01 |
| A Study in Schizophrenic Patients (NCT01125358) | Denovo Biopharma LLC | 2010-05-01 |
| Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia (NCT01324167) | Taipei Medical University WanFang Hospital | 2010-05-01 |
| The Effect of Nicotine on Arousal, Cognition and Social Cognition in Young and Elderly Healthy Subjects. (NCT01181934) | Janssen Pharmaceutica N.V., Belgium | 2010-05-01 |
| Safety and Efficacy of Cariprazine in Schizophrenia (NCT01104779) | Forest Laboratories | 2010-04-27 |
| Safety and Efficacy of Cariprazine in Patients With Schizophrenia (NCT01104766) | Forest Laboratories | 2010-04-23 |
| A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia (NCT01051531) | Janssen Research & Development, LLC | 2010-04-22 |
| Smoking Cessation for Veterans With Severe and Persistent Mental Illness (NCT00960375) | US Department of Veterans Affairs | 2010-04-01 |
| Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ) (NCT01138618) | University of Aarhus | 2010-04-01 |
| GlyT-1 Inhibitor Treatment for Refractory Schizophrenia (NCT01251055) | China Medical University Hospital | 2010-04-01 |
| Zyprexa® Relprevv™ Patient Care Program (NCT01088386) | Eli Lilly and Company | 2010-03-03 |
| A Placebo-Controlled Study of Physiologic Effects of L-methylfolate in Schizophrenia Patients (NCT01091506) | Pamlab, Inc. | 2010-03-01 |
| Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia (NCT01176721) | cerbomed GmbH | 2010-03-01 |
| Database Registry for Neural Network Biomarkers in Psychosis (NCT01409109) | University of Texas Southwestern Medical Center | 2010-03-01 |
| A Study in Schizophrenia Patients (NCT01086748) | Eli Lilly and Company | 2010-03-01 |
| Effect of Varenicline on Cognitive Function in Cigarette Smokers With Schizophrenia (NCT01093365) | Centre for Addiction and Mental Health | 2010-03-01 |
| Huperzine for Cognitive and Functional Impairment in Schizophrenia (NCT00963846) | Biomedisyn Corporation | 2010-03-01 |
| The Prevalence of Obesity For Schizophrenia Inpatients in Taiwan (NCT01170689) | TsaoTun Psychiatric Center, Department of Health, Taiwan | 2010-03-01 |
| First in Man Study of Safety, Tolerability and PK Profile of RBP-7000 (NCT02765555) | Indivior Inc. | 2010-03-01 |
| Factors Association With Poor Physical Function in Older Adults With Schizophrenia (NCT01092598) | University of California, San Francisco | 2010-03-01 |
| A Patient-Centered Approach to Improve Screening for Side Effects of Second Generation Antipsychotics (SGAs) (NCT00677898) | US Department of Veterans Affairs | 2010-03-01 |
| Prevention of Weight Gain in Early Psychoses (NCT01075295) | Centre for Addiction and Mental Health | 2010-02-01 |
| Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia (NCT01164059) | University of Bremen | 2010-02-01 |
| Schizophrenia and Physical Exercise (NCT01595698) | Federal University of São Paulo | 2010-02-01 |
| Mediators and Moderators of Treatment Outcome in Recent-Onset Psychosis (NCT01570972) | University of Arizona | 2010-02-01 |
| Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia (NCT01012167) | University of Maryland, Baltimore | 2010-02-01 |
| Regulation of Arginine-vasopressin (AVP) (NCT02626832) | Yale University | 2010-02-01 |
| Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics (NCT01081769) | Janssen-Cilag International NV | 2010-02-01 |
| Ketamine Challenge Study With JNJ-40411813 (NCT01101659) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2010-02-01 |
| Clinical Symptoms of Schizophrenia and Physical Exercise (NCT01674543) | Federal University of São Paulo | 2010-02-01 |
| Imaging Cannabinoid CB1 Receptors in Schizophrenia (NCT01063335) | National Institute of Mental Health (NIMH) | 2010-02-01 |
| A Pilot Trial of Acute N-Acetylcysteine Effects on Working Memory and Other Cognitive Functions in Schizophrenia (NCT01232790) | Yale University | 2010-02-01 |
| Is MS14 Helpful in Schizophrenia? (NCT01083381) | Farzan Institute | 2010-02-01 |
| Trial for Antidepressant Treatment for Negative Symptom of Schizophrenia With NRG1 Risk Genotype (NCT01078870) | National Taiwan University Hospital | 2010-02-01 |
| Assessing the Impact of Self-directed Care, Within a Medicaid-funded Environment,on Participation and Community Living (NCT02520024) | Temple University Collaborative on Community Inclusion | 2010-01-01 |
| Remediation of Working Memory in Schizophrenia (NCT00995553) | VA Office of Research and Development | 2010-01-01 |
| Mental Healthcare in Older Adults With Schizophrenia (NCT02884739) | CHU de Reims | 2010-01-01 |
| Nicotinic Receptors and Schizophrenia (NCT00952393) | VA Office of Research and Development | 2010-01-01 |
| Study of Vitamin D in the Severely Mentally Ill (NCT01169142) | Bronx Psychiatric Center | 2010-01-01 |
| A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms (NCT01052103) | Denovo Biopharma LLC | 2010-01-01 |
| The Treatment of 2 Chinese Medicines in Clozapine-induced Hypersalivation in Schizophrenia (NCT01045720) | Taichung Veterans General Hospital | 2010-01-01 |
| DECIFER: Depression and Citalopram In First Episode Recovery (NCT01041274) | NYU Langone Health | 2010-01-01 |
| Effects of a Cognitive Rehabilitation Program: a Neurocognitive Study (NCT02201888) | Salvador Sarró, MD | 2010-01-01 |
| Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia (NCT01012830) | VA Nebraska Western Iowa Health Care System | 2009-12-01 |
| Screening Protocol for Research Participants (NCT01010620) | University of Maryland, Baltimore | 2009-12-01 |
| Genes, Intermediate Phenotypes and Response to Quetiapine RX (NCT01044914) | University of Bari | 2009-12-01 |
| Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia (NCT00968851) | FORUM Pharmaceuticals Inc | 2009-12-01 |
| Cannabis and Schizophrenia: Self-Medication and Agonist Treatment (NCT00946348) | Dartmouth-Hitchcock Medical Center | 2009-12-01 |
| Varenicline and Smoking Cessation in Schizophrenia (NCT01111149) | University of Minnesota | 2009-12-01 |
| Study to Evaluate the Efficacy and Safety of GSK239512 in Schizophrenia (NCT01009060) | GlaxoSmithKline | 2009-12-01 |
| Optimizing Cognitive Remediation Outcomes in Schizophrenia (NCT02105779) | University of California, San Francisco | 2009-12-01 |
| Pregnenolone for Cognitive and Negative Symptoms in Schizophrenia (NCT00728728) | VA Office of Research and Development | 2009-12-01 |
| An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia (NCT01009047) | Janssen Research & Development, LLC | 2009-12-01 |
| Efficacy of an Early Antipsychotic Switch in Case of Poor Initial Response to the Treatment of Schizophrenia (NCT01029769) | Technical University of Munich | 2009-12-01 |
| Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography (NCT00942981) | National Institute of Mental Health (NIMH) | 2009-11-13 |
| Internal Monitoring of Eye Movement in Schizophrenia (NCT01011101) | National Eye Institute (NEI) | 2009-11-02 |
| Individually Based Psychosocial Rehabilitation for Older People With Serious Mental Illness (SMI) (NCT00817154) | Dartmouth-Hitchcock Medical Center | 2009-11-01 |
| Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression (NCT01028196) | AstraZeneca | 2009-11-01 |
| Milestones of Adjustment Post-Psychosis (NCT01192594) | Yale University | 2009-11-01 |
| Medication Adherence in Schizophrenia: Development of a CBT-Based Intervention (NCT00980252) | University of Illinois at Chicago | 2009-11-01 |
| A Study Of PF-03463275 As Add-On Therapy In Outpatients With Persistent Negative Symptoms Of Schizophrenia (NCT00977522) | Pfizer | 2009-11-01 |
| Pharmacokinetic Study of ABT-126 in Stable Subjects With Schizophrenia (NCT01043458) | Abbott | 2009-11-01 |
| Oxytocin Treatment of Schizophrenia (NCT01028677) | University of North Carolina, Chapel Hill | 2009-11-01 |
| The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics (NCT00986531) | AstraZeneca | 2009-11-01 |
| Lifestyle Modification for Weight Loss in Schizophrenia (NCT00990925) | Yale University | 2009-10-01 |
| A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children (NCT01050582) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-10-01 |
| Neuromodulation in Depressed and Schizophrenic Patients - Changing MEP (Muscle Evoked Potentials) by tDCS (Transcranial Direct Current Stimulation) (NCT01150734) | Ludwig-Maximilians - University of Munich | 2009-10-01 |
| Competence Ability Study in People With Schizophrenia (NCT01045629) | Taichung Veterans General Hospital | 2009-10-01 |
| Study of Amantadine for Risperidone Consta or Paliperidone Treated Patients to Decrease Prolactin Elevation (NCT00975611) | David C. Henderson, MD | 2009-10-01 |
| The Effect of Ketamine on Attentiveness (NCT01165294) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2009-10-01 |
| TC-5619 as Augmentation Therapy to Improve Cognition in Outpatients With Cognitive Dysfunction in Schizophrenia (NCT01003379) | Targacept Inc. | 2009-10-01 |
| Second-Generation Antipsychotic Treatment Indication Effectiveness And Tolerability In Youth (Satiety) Study (NCT01269710) | University of North Carolina, Chapel Hill | 2009-10-01 |
| Auditory Verbal Hallucinations in Schizophrenia (NCT01886417) | University Hospital, Grenoble | 2009-10-01 |
| Cognitive Behavior Therapy and Work Outcome (NCT00810355) | VA Office of Research and Development | 2009-10-01 |
| Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia. (NCT00716755) | Centre for Addiction and Mental Health | 2009-10-01 |
| A Study Evaluating the Treatment Selection and Outcome When Changing Antipsychotic Treatment in Schizophrenic Patients (NCT00999895) | AstraZeneca | 2009-10-01 |
| Assessing the Effectiveness of Acceptance and Commitment Therapy for Distress Following Psychosis (NCT01003132) | University of Glasgow | 2009-10-01 |
| Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry (NCT00986167) | Bayside Health | 2009-10-01 |
| Effects of Oxytocin Nasal Spray on Social Affiliation (NCT00663039) | University of Maryland, Baltimore | 2009-10-01 |
| Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis (NCT01878513) | Northwell Health | 2009-09-23 |
| Clinical Risk State for Bipolar Disorder in Adolescents (NCT01383915) | Northwell Health | 2009-09-01 |
| L-arginine in Treatment as Usual in Schizophrenia (NCT00718510) | University of Alberta | 2009-09-01 |
| Efficacy and Safety of SEROQUEL Extended Release (XR) in Acute Schizophrenia (NCT00954122) | AstraZeneca | 2009-09-01 |
| Quetiapine XR in Schizophrenic Patients (NCT01071135) | Hannover Medical School | 2009-09-01 |
| Pharmacokinetics, Effect of Food, Safety and Tolerability of a New Tablet Formulation of GSK1144814 in Healthy Subjects (NCT01090440) | GlaxoSmithKline | 2009-09-01 |
| A Study of Olanzapine in Patients With Schizophrenia (NCT00970281) | Eli Lilly and Company | 2009-09-01 |
| Study in Adolescents With Schizophrenia or Bipolar Disorder (NCT00982020) | Eli Lilly and Company | 2009-09-01 |
| Cognitive Remediation in Early Phase Psychosis (NCT01546467) | Oslo University Hospital | 2009-09-01 |
| Metacognitive Training in Schizophrenia (NCT01029067) | Universitätsklinikum Hamburg-Eppendorf | 2009-09-01 |
| Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI (NCT02334280) | Dartmouth-Hitchcock Medical Center | 2009-09-01 |
| Non-interventional (NI) Study to Observe Efficacy and Usage of Quetiapine in Acute Episodes of Schizophrenia and as Maintenance Therapy Following Standard Clinical Practice in Croatia (NCT00981123) | AstraZeneca | 2009-09-01 |
| An Open Trial of Cysteamine Treatment in Schizophrenia (NCT01139125) | Augusta University | 2009-09-01 |
| Epidemiology of Schizophrenia in Bulgaria (NCT00984373) | AstraZeneca | 2009-09-01 |
| A Positron-Emission-Tomography (PET) Study to Measure the Blockade of Dopamine Receptors (D2) in Specific Areas of the Brain in Relation to the Plasma Concentrations of Paliperidone Extended Release (ER) and Oral Risperidone in Schizophrenia Patients and Healthy Controls (NCT00934635) | Janssen-Cilag G.m.b.H | 2009-09-01 |
| Risk Perception in Drug-Dependent Adults With and Without Schizophrenia (NCT01031563) | National Institute on Drug Abuse (NIDA) | 2009-08-18 |
| D-cycloserine Augmentation of Cognitive Remediation in Schizophrenia (NCT00963924) | Massachusetts General Hospital | 2009-08-01 |